Current Status of Skin Cancers With a Focus on Immunology and Immunotherapy Publisher



Khayyati Kohnehshahri M^{1, 2} ; Sarkesh A⁴ ; Mohamed Khosroshahi L⁵ ; Hajiesmailpoor Z⁴ ; Aghebatimaleki A⁶ ; Yousefi M⁷ ; Aghebatimaleki L³
Source: Cancer Cell International Published:2023

Abstract

Skin cancer is one of the most widespread cancers, with a significant global health effect. UV-induced DNA damage in skin cells triggers them to grow and proliferate out of control, resulting in cancer development. Two common types of skin cancer include melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). Melanoma is the most lethal form of skin cancer, and NMSC includes basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and other forms. The incidence of skin cancer is increasing in part owing to a demographic shift toward an aging population, which is more prone to NMSC, imposing a considerable financial strain on public health services. The introduction of immunostimulatory approaches for cancer cell eradication has led to significant improvements in skin cancer treatment. Over the last three decades, monoclonal antibodies have been used as powerful human therapeutics besides scientific tools, and along with the development of monoclonal antibody production and design procedures from chimeric to humanized and then fully human monoclonal antibodies more than 6 monoclonal antibodies have been approved by the food and drug administration (FDA) and have been successful in skin cancer treatment. In this review, we will discuss the epidemiology, immunology, and therapeutic approaches of different types of skin cancer, © 2023, BioMed Central Ltd., part of Springer Nature.